SAN DIEGO, May 14, 2012 /PRNewswire/ -- Volcano
Corporation (NASDAQ: VOLC) today announced its plans to highlight
its extensive product portfolio, strong product pipeline, and
presentations on Fractional Flow Reserve (FFR) and Instant
Wave-Free Ratio™ Functionality (iFR™) at EuroPCR
2012, a major cardiology meeting being held in Paris from May
15 – 18.
"Functional PCI, led by FFR, is front and center at the PCR
meeting this year, with more than 50 individual presentations
throughout the week highlighting the importance of using function
-- and not angiography -- to guide PCI," said Michel Lussier, Group President, Clinical
Affairs and Europe, Middle East, Africa, and India. "Volcano's strong presence at PCR is
tangible evidence of our progress toward helping to create new
standards in precision guided therapy for coronary and peripheral
vascular disease."
Volcano will also showcase a number of new functional
measurement technologies, including the launch of the latest
PRIMEWIRE PRESTIGE® PLUS pressure guidewire, an exploration of its
future pressure and flow products in the company's technology
suite, and various other clinical, educational and technology
showcases throughout EuroPCR 2012, including:
- Wednesday, May 16: 11:12-11:24 a.m. CET
Hotline Session: Physiological
assessment of intermediate coronary stenoses with Instant Wave-Free
Ratio™ Functionality, an adenosine-free pressure-derived index:
results of a multicentre international registry
Presenter: Justin Davies, MD,
PhD
Palais des Congres, Room 252AB
- Wednesday, May 16: 4:30 –
6:00 p.m. CET
Educational Symposium: Functional Assessment of Percutaneous
Interventions with Pressure Guidewires: Will Instant Wave-Free
Ratio™ Functionality Change Your Practice?
Palais des Congres, Room 241
- Thursday, May 17: 1:40 –
3:00 p.m. CET
New Developments in the Assessment of Coronary Stenosis
Presenter: Justin Davies, MD, PhD
(UK & Spain iFR™
Functionality Registry)
Presenter: JJ Park, MD (Independent, Blinded iFR™
Functionality Registry)
Palais des Congres, Room 242B
Product Innovations
Volcano's integrated cath lab systems, coronary and peripheral
IVUS catheters, and Functional Management products will be
available for demonstration at Booth #M71. These products, which
are all available for sale in the U.S. and Europe, include:
- Valet® Microcatheter, which incorporates patented seamless
catheter element transition technology via electrostatic
deposition;
- The PRIMEWIRE PRESTIGE® PLUS pressure guidewire, the latest
innovation in Fractional Flow Reserve wires, designed for
successful navigation in distal anatomy and bifurcations, smooth
device delivery, and functional lesion assessment;
- The Eagle Eye® Platinum Catheter, the #1 digital IVUS catheter
in the world, which provides exceptional deliverability, the
convenience of radiopaque markers, and three imaging modalities
including grayscale IVUS, VH® IVUS and ChromaFlo®
functionality;
- The s5™/s5i® 3.2.2 software, which streamlines the workflow for
both IVUS and FFR procedures and is compatible with more than 3,700
Volcano systems installed worldwide;
- Revolution® 45 MHz Rotational IVUS Imaging Catheter, which is
Volcano's first high frequency catheter;
- Visions® PV .018 Catheter, which is designed specially for
visualization of peripheral vessels: carotids, renals, and
iliacs;
- Visions® PV 8.2 Catheter with new chip technology that provides
increased imaging diameter up to 60 mm and an over-the-wire
catheter design for outstanding trackability and ease of
placement.
Also available in Europe is the
VIBE® RX Vascular Imaging Balloon Catheter, which can quickly
access, prepare, and assess challenging lesions and provide
precise, targeted balloon dilatation with immediate confirmation of
interventional results.
Volcano will also present its pipeline of precision guided
therapy products still in development, including Optical Coherence
Tomography (OCT), Instant Wave-Free Ratio™ Functionality, Forward
Looking imaging including IVUS and ICE applications, and the Eagle
Eye® Platinum – ST IVUS Catheter.
About Volcano Corporation
Volcano Corporation is revolutionizing the medical device
industry with a broad suite of technologies that make imaging and
therapy simpler, more informative and less invasive. Its products
empower physicians around the world with a new generation of
analytical tools that deliver more meaningful information - using
sound and light as the guiding elements. Founded in cardiovascular
care and expanding into other specialties, Volcano is changing the
assumption about what is possible in improving patient outcomes by
combining imaging and therapy together.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical
facts may be considered "forward-looking statements" including
statements regarding the potential benefits of the products and
procedures described above, further development and expansion,
regulatory approval, commercial release and market adoption of the
company's technology, and the impact of clinical and other
technical data. Forward-looking statements are based on
management's current expectations and are subject to risks and
uncertainties which may cause Volcano's results to differ
materially and adversely from the statements contained herein. Some
of the potential risks and uncertainties that could cause actual
results to differ include the pace and extent of market adoption of
the company's products and technologies, growth strategies, timing
and achievement of product development milestones, outcome of
ongoing litigation, the impact and benefits of market development,
product introductions, unexpected new data, safety and technical
issues, market conditions, and other risks inherent to medical
device development and commercialization. These and additional
risks and uncertainties are more fully described in Volcano's
filings made with the Securities and Exchange Commission, including
our recent quarterly report on Form 10-Q. Undue reliance
should not be placed on forward-looking statements which speak only
as of the date they are made. Volcano undertakes no obligation to
update any forward-looking statements to reflect new information,
events or circumstances after the date they are made, or to reflect
the occurrence of unanticipated events.
SOURCE Volcano Corporation